BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company was founded in 1996 and is based in San Rafael, California.
BMRN Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Biomarin Pharmaceutical Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Biomarin Pharmaceutical Inc ranked in the 99th percentile in terms of potential gain offered. As the table below shows, the model suggests the stock is dramatically undervalued -- investors should note, though, that such returns are always unlikely and not to be expected. The most interesting components of our discounted cash flow analysis for Biomarin Pharmaceutical Inc ended up being:
Its compound free cash flow growth rate, as measured over the past 0.25 years, is 4.87% -- higher than 97.44% of stocks in our DCF forecasting set.
The business' balance sheet suggests that 8% of the company's capital is sourced from debt; this is greater than only 22.66% of the free cash flow producing stocks we're observing.
As a business, Biomarin Pharmaceutical Inc experienced a tax rate of about 102% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 93.88% of stocks generating free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as BMRN, try THC, NVAX, KMDA, VRTX, and AMEH.
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN). On August 19, 2020, the Company disclosed that it received a Complete Response Letter (“CRL”) from the FDA rejecting its Biologics License Application (“BLA”) for its product, valoctocogene roxaparvovec, and recommending two years of da
COHERENT MARKET INSIGHTS has added a new report titled Global Cell and Gene Therapy Market with analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. This Cell and Gene Therapy Market